Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and individuals with ARDs not exposed to RTX.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart ...

A new study published in Science Translational Medicine reveals that researchers from MIT and the Scripps Research Institute have developed a potent single-dose HIV vaccine that triggers a ...

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

US FDA grants orphan drug designation to Sanofi’s riliprubart for antibody-mediated rejection in solid organ transplantation: Paris Thursday, June 26, 2025, 09:00 Hrs [IST] The ...

Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in chikungunya-naïve children at day 180.

MIT and Scripps scientists explore a single-dose vaccine approach by combining two immune-boosting ingredients.